Mouse Pax4 (UniProt P32115): research report Claude Code claude-haiku-5-5, claude-opus-5-5 14 citations 2026-11-08T08:09:59.509783

Mouse Pax4 (UniProt P32115): research report

1. Identity check

2. Primary function: a DNA-binding transcriptional repressor

2.1 DNA binding

Smith et al. (1999) cloned a full-length Pax4 cDNA from a beta-cell library. They defined the protein's consensus binding site as a "bipartite consensus DNA binding sequence consisting of a homeodomain binding site separated from a paired domain binding site by 15 nucleotides." The paired half resembles the PAX6 paired-domain site. "The two proteins bind to common sequences in several islet genes, although with different relative affinities" [PMID:10567552, Mol Cell Biol 1999; DOI 10.1128/MCB.19.12.8272].

UniProt states that Pax4 binds "a common element in the glucagon, insulin and somatostatin promoters" and competes with PAX6 for it (PMID:10364449, Ritz-Laser et al. 1999; PMID:10567552). These sites in the glucagon (G1/G3), insulin and somatostatin promoters are among the best-characterised Pax4 target elements.

2.2 Repression

2.3 Molecular function in summary

Pax4 is a sequence-specific, RNA polymerase II–dependent DNA-binding transcription repressor. It binds cis-regulatory sites through both its paired domain and its homeodomain. Its repression domains, chiefly the homeodomain and C-terminus, can act independently of DNA-binding competition. Its main physiological targets are genes that specify alpha-cell (and ghrelin/epsilon-cell) identity, above all Arx. Repression of the hormone genes themselves is shown mostly in cell lines.

3. Where it acts

4. Biological processes and pathway context

4.1 Beta- and delta-cell fate in the pancreatic islet (core role)

Sosa-Pineda et al. (1997) made the Pax4 knockout. It "results in the absence of mature insulin- and somatostatin-producing cells (beta and delta, respectively)... but glucagon-producing alpha cells are present in considerably higher numbers." The authors proposed that "early expression of Pax4 in a subset of endocrine progenitors is essential for the differentiation of the beta and delta cell lineages," with alpha cells as a default fate [PMID:9121556, Nature 1997]. Homozygous mutants develop severe diabetes and die within about three days of birth (UniProt, citing PMID:9121556).

Ghrelin-producing (epsilon) cells also expand in Pax4 mutants. As in Nkx2.2 mutants, "ghrelin cells replace insulin-producing β cells." This points to a shared insulin/ghrelin progenitor, with Nkx2.2 and Pax4 each required independently to specify beta-cell fate (PNAS 2004;101:2924–2929; PMC365721).

4.2 The Arx–Pax4 antagonism (central mechanism)

These studies place Pax4 within the Ngn3-initiated endocrine programme. Pax4 sits downstream of Ngn3, alongside Nkx2.2, and its main output is repression of Arx (the alpha-cell determinant) and of ghrelin/epsilon-cell identity. UniProt records Arx repression as "probably," and strong direct Arx-enhancer binding data for mouse Pax4 were not found.

4.3 Enteroendocrine cell subtype specification

In the mouse intestine, Arx and Pax4 also set enteroendocrine subtypes from Neurog3+ progenitors. Pax4 promotes enterochromaffin (serotonin) and D-cell (somatostatin) fates and restrains Arx-dependent subtypes: L (GLP-1), I (CCK), K (GIP), G and N cells [PMID:22570716, Beucher et al., PLoS One 2012, PMC3343025]. UniProt says this restraint works by repressing ARX, a claim marked "by similarity."

4.4 Adult beta-cell proliferation and survival (secondary, mostly gain-of-function)

Caveat: these are overexpression results. Endogenous Pax4 is barely detectable in adult mouse islets PMID:10567552. They show what Pax4 can do, not established normal adult physiology. They are the likely source of the projected GO terms "negative regulation of apoptotic process" (GO:0043066) and "response to glucose/dexamethasone".

4.5 Limits of the regeneration role

GABA-induced alpha-to-beta-like cell conversion in mice happens through dampened Arx activity. Pax4 is reported as not required for it (Ben-Othman et al., Cell 2017; Silvano/Mansouri/Collombat commentary). Loss of Arx alone in adult alpha cells can also convert them to beta-like cells (Druelle et al.). So Pax4 is enough to reprogram cells but is not required for every route to beta-cell neogenesis. Reviews covering this: PMC4373662; typeset review.

5. Evolutionary and structural inference

6. Notes for annotation

Aspect Well supported Weak or over-annotated
MF RNA Pol II cis-regulatory region sequence-specific DNA binding (GO:0000978); DNA-binding transcription repressor activity, RNA Pol II–specific (GO:0001227) [PMID:10567552, 10891400] Generic DNA binding (GO:0003677) and DNA-binding TF activity (GO:0003700) are true but less specific; double-stranded DNA binding (GO:0003690) is redundant
BP Type B pancreatic cell differentiation/development (GO:0003309) [PMID:9121556, 19665969]; negative regulation of transcription by RNA Pol II (GO:0000122) PMID:10567552; regulation of cell differentiation via enteroendocrine cell differentiation, e.g. enterochromaffin cell differentiation (GO:0035883) PMID:22570716; delta-cell differentiation [PMID:9121556, 15930104] Eye, brain, forebrain and sensory organ development (IBA, family transfer); circadian rhythm, response to glucose/dexamethasone, and anti-apoptosis (ISO/ISS from rat/human overexpression); insulin secretion-related terms
CC Nucleus; chromatin (inferred) Transcription regulator complex (GO:0005667) has no direct complex data

7. Open questions and suggested experiments

  1. Map genome-wide Pax4 occupancy in E13.5–E15.5 endocrine progenitors (CUT&RUN/ChIP-seq on epitope-tagged endogenous Pax4) to test whether Arx and ghrelin are direct targets.
  2. Identify the corepressors behind the homeodomain and C-terminal repression domains, for example by Groucho/TLE or Sin3 proximity labelling, and test them with repression-domain mutants in vivo.
  3. Test whether endogenous Pax4 has any adult beta-cell role (inducible beta-cell-specific deletion under metabolic stress), given that the proliferation and survival data come from overexpression.

Sources

How the sources were checked:
- The abstracts of PMIDs 9121556, 10567552, 10891400, 14561778, 19665969 and 22570716 were read from the local publications/ cache.
- PMIDs 10364449 and 15930104 are cited through UniProt and partial abstracts.
- The Lorenzo 2011 and PNAS 2004 details come from web search snippets, not full texts.
- No source from 2023–2026 specific to mouse Pax4 mechanism was found, so the core picture rests on the 1997–2012 primary literature.

Citations

  1. https://bmcdevbiol.biomedcentral.com/track/pdf/10.1186/1471-213X-9-65
  2. https://ediss.uni-goettingen.de/handle/11858/00-1735-0000-0006-ABEE-6;jsessionid=AAEABBFBEB387A45BCB6AA55D28F895B
  3. https://jci.org/references/scholar/35112/B11
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC365721/
  5. https://www.biomedcentral.com/1471-213X/11/52
  6. https://rupress.org/jcb/article/167/6/1123/51557/The-diabetes-linked-transcription-factor-PAX4
  7. https://scite.ai/authors/nouha-ben-othman-4YZ8k3
  8. https://pure.mpg.de/pubman/item/item_2468345_3/component/file_2468346/2468345.pdf
  9. https://scite.ai/authors/noemie-druelle-lXZ2r3
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4373662
  11. https://typeset.io/pdf/role-of-transcription-factors-in-the-transdifferentiation-of-3io36ih86i.pdf
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC218152
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2792203
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3561089